基础医学与临床2011，Vol.31Issue(7)：783-787,5.
自体Retronectin诱导的CIK细胞治疗晚期结肠癌的疗效观察
Therapeutic effects of autologous Retronectin activated CIK killer cell immunotherapy for patients with advanced colon carcinoma
摘要
Abstract
Objective To study the therapeutic safety and effects of autologous Retronectin activated CIK cell immunotherapy for patients with advanced colon carcinoma. Methods CIK cells were isolated from peripheral blood mononuclear cells (PBMC) and incubated in the presence of IFN-γ followed by Retronectin, mouse antihuman CD3 monoelonal antibody and IL-2. Then, CIK cells were intravenously transfused every week for at least 4 weeks.Immunophenotypic characteristics of CIK cells were analyzed by flow cytometry. IFN-γ, tumour necrosis factor α (TNF-α), IL-2, IL-10 and IL-4 concentrations in serum were determined with BDTM human Cytometric Bead Array kits (CBA). Results The median number of transferred cells per patient was 23.9 × 109/L (20. 6 × 109 ～27. 2 × 109) , and the toxicity profile was favourable. After CIK cells infusion, the absolute median count of lymphoeytes, CD3 + , CD8 + and CD3 + CD56 + cells significantly increased in patient's peripheral blood. One patients had partial response (PR) and four patients had stabilization of disease(SD). The downtrend of the CEA level was observed in the PR and two SD patients. The patients with positive response after treatment increased the production of IFN-γ (6. 9 vs 53.2 pg/mL) and TNF-α (3.2 vs 24. 6 pg/mL). No significant difference was seen in non-responders and in the expression of other cytokines. Conclusion Adoptive immunotherapy with Retronectin induces CIK cells and is a safe it could significantly enhance immune functions without side effects.关键词
结肠癌/CIK/免疫功能Key words
colon carcinoma/ CIK/ immune function分类
医药卫生引用本文复制引用
徐本玲,高全立,袁龙,范瑞华,张成娟,宋永平..自体Retronectin诱导的CIK细胞治疗晚期结肠癌的疗效观察[J].基础医学与临床,2011,31(7):783-787,5.基金项目
河南省医学科技攻关计划项目(201001012) （201001012）
